Medico Intercontinental Ltd. Stock Analysis 539938.BO

Medico Intercontinental Ltd. engages in the business of financing, trading and investment in shares and securities. The company is headquartered in Ahmedabad, Gujarat. The company went IPO on 2016-06-17. The company provides a platform for all research-based biopharmaceutical companies. Its product categories include Gastro, Uro, Nutrition, Cosmetology, Health devices, Hospital, and other areas. Its products include ACIFACT-BLI, ACIFACT-P, ACIFACT-SP (ALU-ALU), ALBECTIN, ALFACARE-D3, ARSUFACT Combokit, BALOFACT, CYCLOFACT 400, UDIFACT 150, XOFACT-4, ZIFT SL-250, ZYMIX, ARGIFACT, CLIANCIACT POWDER, RELIEVE CZ, VOLIREX SPRAY, RACIMAX SACHET, PERMACT, OROFACT, KTZ, FEMYACT, LIVOFACT, ZYMIX SY, ULTRATONE SY, ALBECTIN SUS, BECOFACT DROPS, MEFACT P SUS, ONCARE SOLUTION, OFCARE-FORTE SUS, PRODOM CV SY, RELIBEN SUSP, ZIFT SUSP-200, MGCIPACT EYE DROP, OROFACT-PASTE (lamy), OROFACT MOUTH ULCER GEL, CAMBOGIA, LUBRIACT, HIZEN, and CALAMED LOTION. Its subsidiaries include Evagrace Pharma Private Limited, Ritz Formulations Private Limited, Sungrace Pharma Private Limited, and Azillian Healthcare Private Limited.